News | Stereotactic Body Radiation Therapy (SBRT) | March 20, 2017

SBRT Offers Curative Option for Lung Cancer Patients 80 and Older

Highly targeted radiation therapy is well tolerated and effectively limits cancer spread for elderly patients with inoperable early-stage disease

SBRT, stereotactic body radiation therapy, early-stage lung cancer, patients 80 and older, 2017 Multidisciplinary Thoracic Cancers Symposium, study

March 20, 2017 — Patients in their 80s and 90s who have early-stage lung cancer but cannot undergo an operation can be treated safely and effectively with stereotactic body radiation therapy (SBRT), according to research presented at the 2017 Multidisciplinary Thoracic Cancers Symposium. The advanced form of radiation therapy (RT) was well tolerated among this relatively understudied elderly population, indicating that SBRT is a viable option for patients who may otherwise be offered no curative treatment.

While the primary treatment for early-stage lung cancer is surgical removal of the tumor, some patients may not be able to tolerate surgery due to health status, advanced age or other factors. For these patients, the best curative option is SBRT, a specialized type of external beam radiation therapy (RT) that uses advanced imaging techniques to deliver extremely targeted radiation to a tumor. This high degree of precision makes SBRT particularly effective at sparing surrounding healthy tissue, which is important for tumor sites near essential organs, such as the heart and lungs. Patients complete SBRT treatment in three to five days, compared with several weeks for conventional RT.

"While multiple studies and trials have established the effectiveness of SBRT for inoperable early-stage lung cancer, one of the common reasons for not giving radiation in older patients is concern about tolerating the treatment and potential side effects," said Richard J. Cassidy III, M.D., lead author of the study and a resident in radiation oncology at Emory University's Winship Cancer Institute in Atlanta. "The low rates of side effects from SBRT for this elderly population in our study indicate that these concerns should not prevent physicians from considering definitive treatment for their inoperable octogenarian and nonagenarian patients with early-stage lung cancer."

Findings are based on a retrospective analysis of 58 consecutive patients who received definitive lung SBRT across four academic sites within Emory between 2010 and 2015. All patients were age 80 or older at the time of their diagnosis, with a median age of 84.9 years. Forty percent of the tumors were adenocarcinomas, while 29 percent were squamous cell carcinomas and 31 percent did not have a biopsy. Fifty percent of patients who did not have a biopsy had a previous history of lung cancer. Researchers used logistic regression and proportional hazard testing to determine the association of patient, tumor and treatment characteristics to compare rates of survival, recurrence and progression and assess the influence of patient and disease characteristics. Recursive partitioning analysis (RPA) was conducted to determine which patients were most likely to benefit from therapy.

At two years following definitive SBRT for lung cancer among elderly patients, survival rates were 73 percent for cancer specific survival (CSS) and 57 percent for overall survival (OS). CSS rates were higher for patients who were not active smokers but lower for patients who were older or had a previous lung cancer diagnosis (smoking Hazard Ratio (HR) = 0.14, p = 0.03; age HR = 1.19, p = 0.04; cancer HR = 7.75, p = 0.01). OS rates were higher for patients with higher Karnofsky Performance Status (KPS), which measures a patient's functional ability to perform ordinary tasks, such as work and self-care (HR = 0.91; p < 0.01). Researchers determined that this metric should be considered when offering SBRT in this elderly population, with certain performance status criterion (i.e., KPS ≥ 75) associated with significantly improved outcomes.

Two-year estimates of local control and regional control were 84.5 percent and 71.7 percent, respectively. Local failure was more common among patients with adenocarcinomas (HR = 6.36, p = 0.01) and less common for patients with T1 tumors (HR = 0.20, p < 0.01). Higher KPS scores were associated with lower rates of both local failure (HR = 0.92, p < 0.01) and regional failure (HR = 0.94, p < 0.01). In terms of toxicity, just over one-third of patients (34.5 percent) experienced radiation pneumonitis of any grade, with only two patients experiencing grade 3+ pneumonitis. Pneumonitis was more frequent among patients who were not actively using ace-inhibitors (Odds Ratio (OR) = 3.49, p = 0.02) and less frequent in smaller tumors (OR = 0.03, p < 0.01).

"Our study, along with other studies, helps to show that SBRT can effectively and safely add years to the lives of elderly patients who have early-stage lung cancer but cannot undergo an operation for it," said Cassidy. "Elderly patients, who are otherwise doing well, should not have treatment withheld based solely on concerns about side effects and age."

For more information:

Related Content

Turkish Hospital Begins MR-Guided Radiation Therapy With Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | September 21, 2018
ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's...
Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
SimonMed Deploys ClearRead CT Enterprise Wide
News | Computer-Aided Detection Software | September 17, 2018
September 17, 2018 — National outpatient physician radiology group SimonMed Imaging has selected Riverain Technologie
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Veye Chest version 2
News | Lung Cancer | September 11, 2018
Aidence, an Amsterdam-based medical AI company, announced that Veye Chest version 2, a class IIa medical device, has
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Check-Cap Announces Interim Results of European Study of C-Scan System Version 3
News | Colonoscopy Systems | September 04, 2018
Check-Cap Ltd. announced the interim results for its post-CE approval study of the C-Scan system Version 3, an...
Brain Iron Levels May Predict Multiple Sclerosis Disabilities
News | Neuro Imaging | August 31, 2018
A new, highly accurate magnetic resonance imaging (MRI) technique can monitor iron levels in the brains of multiple...